Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan
Neurology and Therapy · 2026-08 · 15 (4) · 1539-1555
DOI: 10.1007/s40120-026-00938-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neurology and Therapy, online erschienen am 25.04.2026. Verfasst von Norio Chihara und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Alexion, AstraZeneca Rare Disease.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan.
- Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA, USA.
- Alexion Pharma GK, Tamachi Station Tower N, 3-1-1, Shibaura, Minato-ku, Tokyo, 108-0023, Japan. naoki.numajiri@alexion.com.
- Department of Neurology, Tohoku University Hospital, 1-1 Seiryomachi, Aoba Ward, Sendai, Japan.
Förderung
- Alexion, AstraZeneca Rare Disease
Zitieren
APA
Chihara, N., Lee, J., Yu, J. C., Numajiri, N., & Misu, T. (2026). Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan. Neurology and Therapy, 15(4), 1539-1555. https://doi.org/10.1007/s40120-026-00938-8
Vancouver
Chihara N, Lee J, Yu JC, Numajiri N, Misu T. Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan. Neurology and Therapy. 2026;15(4):1539-1555. doi:10.1007/s40120-026-00938-8
BibTeX
@article{Chihara2026,
author = {Chihara, Norio and Lee, Justin and Yu, Jeffrey C and Numajiri, Naoki and Misu, Tatsuro},
title = {Real-World Treatment Adherence and Persistence with C5 Inhibitor Therapy Versus Satralizumab in Patients with Neuromyelitis Optica Spectrum Disorder in Japan},
journal = {Neurology and Therapy},
year = {2026},
volume = {15},
number = {4},
pages = {1539--1555},
doi = {10.1007/s40120-026-00938-8}
}
EUVIMED